IngevityNGVT
NGVT logo
Fair Value
US$89
Share price04 Jul
US$71.619.6% undervalued intrinsic discount
Loading
1Y52.02%
7D-3.06%

Portfolio Repositioning And Engineered Additives Will Create A Sustainable Future

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
27 May 25
Updated
04 Jul 26
Views
155
Not Invested

Last Update 04 Jul 26

Fair value Increased 4.09%

NGVT: Share Repurchases And 2026 Guidance Will Support Future P/E Rerating

Analysts have modestly raised their price target for Ingevity to $89.0 from $85.5, citing updated assumptions that include a smaller expected revenue decline, a slightly lower discount rate, and a marginally reduced profit margin and future P/E ratio.

What’s in the News for Ingevity

  • Ingevity reaffirmed full year 2026 earnings guidance, with expected net sales in a range of $1.05b to $1.15b. (Source: Key Developments)
  • From January 1, 2026 to March 31, 2026, Ingevity repurchased 774,189 shares for US$51.94 million, representing 2.18% of its shares. (Source: Buyback Tranche Update)
  • Under the share repurchase program announced on August 2, 2022, Ingevity has completed the buyback of 3,887,802 shares, representing 10.6% of its shares, for a total of US$254.45 million. (Source: Buyback Tranche Update)

Valuation Changes for Ingevity

  • Fair Value: Increased slightly to $89.0 from $85.5.
  • Discount Rate: Reduced marginally to 8.03% from 8.06%.
  • Revenue Growth: The assumed revenue decline has narrowed, now falling 1.35% instead of 3.93%.
  • Net Profit Margin: Trimmed modestly to 30.98% from 31.94%.
  • Future P/E: Lowered slightly to 9.61x from 9.70x.
3 viewsusers have viewed this narrative update

Key Takeaways

  • Strategic divestitures and operational optimization drive focus on high-value specialty chemicals, boosting margins, efficiency, and free cash flow resilience.
  • Innovation investment and global expansion into sustainable applications support long-term growth, business diversification, and margin stability.
  • Ongoing segment weakness, trade uncertainties, portfolio shifts, and rising competition threaten margin stability, revenue growth, and future earnings reliability.

Catalysts

About Ingevity
    Manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America.
What are the underlying business or industry changes driving this perspective?
  • Accelerated portfolio repositioning and the advanced-stage divestiture of non-core, lower-margin businesses (Industrial Specialties and CTO refinery) are expected to drive a step-change in margin profile, enabling greater focus and capital allocation toward higher-growth, value-added specialty chemicals-supporting both revenue quality and sustained EBITDA margin improvement.
  • Substantial investments in innovation and engineered additives, especially in applications such as EV battery materials (via the Nexeon partnership) and process purification, position Ingevity to capture new demand arising from the increased global focus on sustainability and decarbonization-providing future top-line growth opportunities as industries transition to green technologies.
  • Structural optimization of operational footprint, resulting in lower maintenance CapEx and improved manufacturing efficiency, is freeing up cash flow while lowering cost per unit, directly enhancing free cash flow generation and improving net earnings resiliency.
  • Pricing power in high-value Performance Materials, supported by long-standing customer relationships and differentiated proprietary technologies, continues even in soft-volume environments and tariff uncertainty-demonstrating business resilience and enabling above-average net margin retention.
  • Organic and geographic expansion plans, paired with ongoing portfolio review targeting high-growth applications and regions (such as Asia-Pacific and green infrastructure), are expected to reduce cyclicality and broaden the addressable market, positively impacting future revenue diversification and long-term earnings stability.
Ingevity Earnings and Revenue Growth

Ingevity Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Ingevity's revenue will decrease by 1.4% annually over the next 3 years.
  • Analysts assume that profit margins will increase from -13.2% today to 31.0% in 3 years time.
  • Analysts expect earnings to reach $350.3 million (and earnings per share of $6.24) by about July 2029, up from -$156.0 million today.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 9.7x on those 2029 earnings, up from -16.2x today. This future PE is lower than the current PE for the US Chemicals industry at 25.7x.
  • Analysts expect the number of shares outstanding to decline by 4.65% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 8.03%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • APT (Advanced Polymer Technologies) segment suffered a non-cash goodwill impairment charge of $184 million this quarter, with ongoing tariff-related uncertainty and persistent weakness in global industrial markets leading to reduced demand and lower EBITDA margins (now guided only at 15–20%), threatening long-term revenue and margin stability.
  • Company remains exposed to cyclical downturns in key industrial and automotive end-markets-recent headwinds in Europe and Asia and cautious auto production forecasts outside China highlight vulnerability to macroeconomic and regulatory shifts, impacting long-term revenues and earnings.
  • Indirect and direct tariff impacts have meaningfully reduced customer demand, especially in global APT markets like automotive, footwear, and apparel-prolonged tariff uncertainties and shifts in global trade patterns could further erode future revenues and net margins.
  • The company's reliance on legacy segments (e.g., activated carbon, pine-chemical-derived products) and ongoing portfolio rationalization-such as the planned sale of the Industrial Specialties business and CTO refinery-adds business model uncertainty and may introduce future earnings volatility if asset divestitures or repositioning strategies fail to deliver anticipated synergies.
  • Rising competitive pressures and the need for price concessions in the APT segment (in part to address global competitive dynamics) suggest risk of margin compression and potential loss of market share to more innovative or sustainable chemical producers, challenging long-term earnings growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of $89.0 for Ingevity based on their expectations of its future earnings growth, profit margins and other risk factors.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.1 billion, earnings will come to $350.3 million, and it would be trading on a PE ratio of 9.7x, assuming you use a discount rate of 8.0%.
  • Given the current share price of $72.49, the analyst price target of $89.0 is 18.6% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Ingevity?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value vs Share Price

US$89
vs US$71.619.6% undervalued intrinsic discount
PastFuture-354m2b2015201820212024202620272029Revenue US$1.1bEarnings US$350.3m
-1.4%
Revenue growth
31%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Ingevity

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Fair value with moderate growth potential.

Market capUS$2.5b
PB64.0x
Estimated Growth-0.5%
Dividend YieldN/A
Full analysis

CEO & management

David Li
CEO
1.0yrs
CEO Tenure

Manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America.